Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Bálint Lőrinczi
 + 905 word(s) 905 2021-11-09 10:41:44 |
2 Done
Jason Zhu
 Meta information modification 905 2021-11-15 03:20:17 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Lőrinczi, B. Mannich-type substitution of KYNA derivatives. Encyclopedia. Available online: https://encyclopedia.pub/entry/15946 (accessed on 27 July 2024).
Lőrinczi B. Mannich-type substitution of KYNA derivatives. Encyclopedia. Available at: https://encyclopedia.pub/entry/15946. Accessed July 27, 2024.
Lőrinczi, Bálint. "Mannich-type substitution of KYNA derivatives" Encyclopedia, https://encyclopedia.pub/entry/15946 (accessed July 27, 2024).
Lőrinczi, B. (2021, November 12). Mannich-type substitution of KYNA derivatives. In Encyclopedia. https://encyclopedia.pub/entry/15946
Lőrinczi, Bálint. "Mannich-type substitution of KYNA derivatives." Encyclopedia. Web. 12 November, 2021.
Mannich-type substitution of KYNA derivatives
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms222111935

Kynurenic acid (KYNA) is an endogenous neuroprotective agent of increasing importance. Several derivatives have already been synthesized, bearing an abundance of functional groups attached to the main skeleton in different positions. Several of these compounds have already been tested in biological evaluations, with several of them targeting the same receptors and biological effects as KYNA.

kynurenic acid modified Mannich reaction kynurenic acid derivatives neuroprotection blood-brain-barrier

1. Introduction

Among the important features of KYNA, it is one of few known endogenous excitatory amino acid receptor blockers with a broad spectrum of antagonistic properties in supraphysiological concentrations. It is well established that KYNA has a high affinity towards N-methyl-D-aspartate (NMDA) receptors. Moreover, it has recently been disclosed that KYNA shows an even higher affinity towards positive modulatory binding sites at α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [1].

Since KYNA is a neuroprotective agent able to prevent neuronal loss following excitotoxic, ischemia-induced, and infectious neuronal injuries [2][3], there has recently been increasing interest in the synthesis and pharmacological studies of KYNA derivatives. The substitution of KYNA at positions 5–8 was achieved by starting from the corresponding aniline via the modified Conrad–Limpach method [4][5][6]. The hydroxy group at position four was transformed to ether [6][7][8] or amine functions [9][10][11], while the carboxylic function at position two was mostly modified into the corresponding esters [6][7][8] or amides [12][13][14][15][16][17].

2. Mannich-Type Transformations of KYNA and Its Substituted Derivatives

2.1. C-3 Substitutions of KYNA Derivatives

Formally, KYNA can be considered to be a nitrogen-containing 1-naphthol derivative. Based upon their previous works with 1-naphthol and its N-containing analogs [18][19][20][21], Szatmári et al. successfully applied the ethyl ester of KYNA in the modified Mannich reaction (mMr) [22]. In this regard, to explore the scope and limitations of the reaction, different primary and secondary amines (acyclic and cyclic) were reacted with KYNA in the presence of formaldehyde (22% solution) in an optimized reaction condition of 1,4-dioxane as solvent under reflux conditions with a 5 h reaction time. The synthesis all yielded the C-3 aminoalkylated kynurenic acid derivatives 118-126 (Scheme 1, Table 1).
Scheme 1. Synthesis of KYNA and B-ring substituted KYNA Mannich derivatives.
Table 2. KYNA Mannich derivatives.
Compound # R2 R3 R4 Yield (%)
118 H 2-morpholinoethyl H 78
119 H 2-(dimethylamino)ethyl Ph 74
120 Me Me H 82
121 Me Bz H 85
122 morpholine H 91
123 piperidine H 73
124 N-methyl-piperazine H 78
125 1,2,3,4-tetrahydroisoquinoline H 81
126 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline H 72
To test the effect of substituents at positions 5, 6, 7 or 8 on the mMr, derivatives 111b–e were reacted with morpholine as a representative secondary cyclic amine in the presence of formaldehyde. Reactions were carried out under the optimized reaction conditions, concluding that aryl/alkyl substituents at position 6 or 8 and the halogen at position 5 or 7 have no significant influence on the aminoalkylation at C-3 (Scheme 2, 127–130).

2.2. Aminoalkylations of Hydroxy-KYNA Derivatives

Regarding the 1-naphthol analogy of KYNA, the B-ring substituted derivatives show possibilities for further fascinating mMr transformations. Compounds 114c, 131 through their analogy with 1-naphthol and 114a,b through their 2-naphthol analogy (Figure 1), offer new possible reaction routes for the aminoalkylation.
Figure 1. Structures of hydroxy-KYNA derivatives.

2.2.1. Derivatives with Structural Similarities to 1-Napthol

Hydroxylated KYNA derivatives bearing the secondary hydroxy function at position 5 or 8 show a second 1-napthol similarity. In this case, the aminoalkylations can be expected to first undergo it in position 6 or 7, respectively, as these positions can both be regarded as the C-2 and, consequently, the most reactive position of a 1-napthol skeleton, as well as the sterically-less hindered position of the KYNA skeleton. However, this substitution route was observed by Szatmári et al. only in the case of compound 114c, the reactions first yielding 132, and subsequently 133. The morpholinomethylation in the case of the 8-hydroxy derivative (131) first took place at C-3, yielding 134 and only after that at C-7 (Scheme 3, 135) [23].
In both cases, DFT calculations were carried out to support the observed results, showing that the reason behind the sluggish and irregular reactivity of 131 might be due to its low HOMO energy level.
Scheme 2. Aminoalkylations of the ethyl esters of 5- and 8-hydroxykynurenic acids. (i) 114c:morpholine:(CH2O)n 1:1:3; EtOH, MW, 150 °C, 1 h; (ii) 114c:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 2 h; (iii) 131:morpholine:(CH2O)n 1:1:3; dioxane, MW, 150 °C, 2 h; (iv) 131:morpholine:(CH2O)n 1:3:4.6; toluene, MW, 80 °C, 1 h.

2.2.2. Derivatives with Structural Similarities to 2-Napthol

In the case of the 6- and 7-hydroxykynurenic acids (114a,b), a similarity between the skeleton and 2-naphthol can be observed, implicating that the aminoalkylations may take place in position 5 or 7, respectively. After performing the reactions, it has been observed that only compound 114b shows the expected reactivity with the morpholinomethyl function first forming at position C-8 (138) and subsequently in position C-3 (Scheme 41, 139). In the case of compound 114a, the reaction first led to the formation of the C-3 substituted derivative and later to the formation of the disubstituted derivative (136 and 137). This unexpected reactivity was later investigated by DFT calculation disclosing HOMO delocalization and local NBO charges for the corresponding anion pairs theorized to form during the reaction. These calculations were in line with the experimental results implying that in the case of 114a, despite the similarity to 2-naphthol, the additional functional groups and heteroatom in the ring-system may override the reactivity expected from the sterically-less hindered 2-naphthol skeleton, resulting in the formation of 136 as a primary product [23].
Scheme 3. Morpholinomethylations of the ethyl esters of 6- and 7-hydroxykynurenic acids. (i) 114a:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 30 min; (ii) 114a:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 2 h; (iii) 114b:morpholine:(CH2O)n 1:1:3; EtOH, MW, 80 °C, 1.5 h; (iv) 114b:morpholine:(CH2O)n 1:2:4; EtOH, reflux, 56 h.

References

  1. Sas, K.; Robotka, H.; Toldi, J.; Vécsei, L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 2007, 257, 221–239.
  2. Gigler, G.; Szénási, G.; Simó, A.; Lévay, G.; Hársing, L.G., Jr.; Sas, K.; Vécsei, L.; Toldi, J. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur. J. Pharmacol. 2007, 564, 116–122.
  3. Luchowska, E.; Luchowski, P.; Sarnowska, A.; Wielosz, M.; Turski, W.A.; Urbańska, E.M. Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus. Pol. J. Pharmacol. 2003, 55, 443–447.
  4. Harrison, B.L.; Baron, B.M.; Cousino, D.M.; McDonald, I.A. 4-- and 4--5,7-dichloroquinoline-2-carboxylic acid: New antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate (NMDA) receptor complex. J. Med. Chem. 1990, 33, 3130–3132.
  5. Edmont, D.; Rocher, R.; Plisson, C.; Chenault, J. Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents. Bioorg. Med. Chem. Lett. 2000, 16, 1831–1834.
  6. Bonina, F.P.; Arenare, L.; Ippolito, R.; Boatto, G.; Battaglia, G.; Bruno, V.; De Caprariis, P. Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int. J. Pharm. 2000, 202, 79–88.
  7. Manfredini, S.; Pavan, B.; Vertuani, S.; Scaglianti, M.; Compagnone, D.; Biondi, C.; Scatturin, A.; Tanganelli, S.; Ferraro, L.; Prasad, P.; et al. Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity. J. Med. Chem. 2002, 45, 559–562.
  8. Manfredini, S.; Vertuani, S.; Pavan, B.; Vitali, F.; Scaglianti, M.; Bortolotti, F.; Biondi, C.; Scatturin, A.; Prasad, P.; Dalpiaz, A. Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules. Bioorgan. Med. Chem. 2004, 12, 5453–5463.
  9. Yielding, K.L.; Nichols, A.C. Anticonvulsant activity of antagonists for the NMDA-associated glycine binding site. Mol. Chem. Neuropathol. 1993, 19, 269–282.
  10. Stone, T.W. Inhibitors of the kynurenine pathway. Eur. J. Med. Chem. 2000, 35, 179–186.
  11. Nichols, A.C.; Yielding, K.L. Anticonvulsant activity of 4-urea-5,7-dichlorokynurenic acid derivatives that are antagonists at the NMDA-associated glycine binding site. Mol. Chem. Neuropathol. 1998, 35, 1–12.
  12. Füvesi, J.; Somlai, C.; Németh, H.; Varga, H.; Kis, Z.; Farkas, T.; Károly, N.; Dobszay, M.; Penke, Z.; Penke, B.; et al. Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol. Biochem. Behav. 2004, 77, 95–102.
  13. Zhang, L.; Sun, F.; Li, Y.; Sun, X.; Liu, X.; Huang, Y.; Zhang, L.H.; Ye, X.S.; Xiao, J. Rapid Synthesis of Iminosugar Derivatives for Cell-Based In Situ Screening: Discovery of “Hit” Compounds with Anticancer Activity. ChemMedChem 2007, 2, 1594–1597.
  14. Brik, A.; Lin, Y.C.; Elder, J.; Wong, C.H. A quick diversity-oriented amide forming reaction coupled with in situ screening as an approach to identify optimal p-subsite residues of HIV-1 protease inhibitors. Chem. Biol. 2002, 9, 891–896.
  15. Tossi, A.; Benedetti, F.; Norbedo, S.; Skrbec, D.; Berti, F.; Romeo, D. Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. Bioorg. Med. Chem. 2003, 11, 4719–4727.
  16. Knyihár-Csillik, E.; Mihály, A.; Krisztin-Péva, B.; Robotka, H.; Szatmári, I.; Fülöp, F.; Toldi, J.; Csillik, B.; Vécsei, L. The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: Comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci. Res. 2008, 61, 429–432.
  17. Fülöp, F.; Szatmári, I.; Vámos, E.; Zádori, D.; Toldi, J.; Vécsei, L. Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr. Med. Chem. 2009, 16, 4828–4842.
  18. Szatmári, I.; Fülöp, F. Syntheses, transformations and applications of aminonaphthol derivatives prepared via modified Mannich reactions. Tetrahedron 2013, 69, 1255–1278.
  19. Szatmári, I.; Fülöp, F. Microwave-Assisted One-Pot Synthesis of (Aminoalkyl)naphthols and (Aminoalkyl)quinolinols by Using Ammonium Carbamate or Ammonium Hydrogen Carbonate as Solid Ammonia Source. Synthesis 2009, 5, 775–778.
  20. Szatmári, I.; Fülöp, F. Simple access to pentacyclic oxazinoisoquinolines via an unexpected transformation of aminomethylnaphthols. Tetrahedron Lett. 2011, 52, 4440–4442.
  21. Sas, J.; Szatmári, I.; Fülöp, F. C-3 functionalization of indole derivatives with isoquinolines. Curr. Org. Chem. 2016, 20, 2038–2054.
  22. Lőrinczi, B.; Csámpai, A.; Fülöp, F.; Szatmári, I. Synthesis of new C-3 substituted kynurenic acid derivatives. Molecules 2020, 25, 937.
  23. Lőrinczi, B.; Csámpai, A.; Fülöp, F.; Szatmári, I. Synthetic-and DFT modelling studies on regioselective modified Mannich reactions of hydroxy-KYNA derivatives. RSC Adv. 2021, 11, 543.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biochemical Research Methods
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Bálint Lőrinczi
View Times: 375
Revisions: 2 times (View History)
Update Date: 15 Nov 2021
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback